1. Medtech Insight
  2. >>Archive

Industry still waiting for details of common technical specifications under IVD (in vitro diagnostic) Directive

Industry in Europe is still none the wiser as to exactly which in vitro diagnostic (IVD) products perceived as having a high degree of potential risk will be subject to specific technical requirements or controls - the so-called common technical specifications (CTSs) - under the new IVD Directive when it takes effect next year. There has been progress on the matter, however.

Industry in Europe is still none the wiser as to exactly which in vitro diagnostic (IVD) products perceived as having a high degree of potential risk will be subject to specific technical requirements or controls - the so-called common technical specifications (CTSs) - under the new IVD Directive when it takes effect next year. There has been progress on the matter, however.

CTSs, which are intended to ensure a common approach for pre-market assessment for high-risk diagnostics and thereby ensure consistency of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.